Abingworth
Vincent has more than 40 years’ experience in the biotechnology industry in a broad range of functions. He identifies and invests in new businesses and supports portfolio companies. His recent Board positions have included IFM Therapeutics, IFM Tre, IFM Due, Personalis and Hydra Biosciences. Earlier Board positions included Chiasma, Dicerna Pharmaceuticals, Dynex Technologies, Magellan Diagnostics and PrimeraDx. Before joining Abingworth in 2007 he was Senior Vice President, Business Development, of Alnylam Pharmaceuticals (a former Abingworth portfolio company).
Previously, Vincent was at Millennium Pharmaceuticals where he held VP positions in business development, strategic planning and corporate communications. Earlier, he was Director of the technology transfer office at the Dana-Farber Cancer Institute and held VP positions in business development and R&D at RiboGene and Pharmacia. He began his career in R&D at Amersham International. He has a BSc in Biochemistry and a PhD in Biochemical Embryology (molecular biology) from University College London.
This person is not in any teams
This person is not in any offices
Abingworth
1 followers
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors. Supporting its portfolio companies with a team of 25 at offices in London, Menlo Park, and Boston, Abingworth has invested in 151 life science companies, completed 65 IPOs and 42 mergers and acquisitions.